GPRC5C (G Protein-Coupled Receptor Class C Group 5 Member C) is a member of the orphan G protein-coupled receptor (GPCR) family, characterized by its seven transmembrane domains and structural similarity to metabotropic glutamate receptors. It belongs to the C5 subgroup of GPCRs, which includes retinoic acid-inducible receptors (GPRC5A-C). While its exact physiological role remains unclear, GPRC5C is implicated in diverse processes such as tissue homeostasis, metabolism, and cancer progression. Studies suggest its involvement in lipid metabolism regulation, particularly in adipose tissue, and potential roles in insulin sensitivity and obesity-related pathways. In cancer, GPRC5C exhibits context-dependent behaviors, acting as a tumor suppressor in some contexts (e.g., prostate cancer) while promoting metastasis in others (e.g., breast cancer). Its expression patterns vary across tissues, with higher levels observed in metabolic organs like adipose tissue and liver. GPRC5C antibodies are critical tools for detecting its expression, localization, and post-translational modifications. These antibodies enable applications including Western blotting, immunohistochemistry, and flow cytometry, supporting research into metabolic disorders, oncogenesis, and receptor signaling mechanisms. Commercial antibodies are typically raised against specific epitopes, such as extracellular loops or intracellular domains, with validation in knockout models to ensure specificity. Ongoing research aims to clarify its endogenous ligands and downstream effectors, positioning GPRC5C as a potential therapeutic target for metabolic diseases and cancer.